title: [Comparison of nicardipine and isradipine in hypertension following coronary artery bypass graft].
abstract: OBJECTIVE
  Compare the efficacy of isradipine to that of nicardipine for the control of arterial hypertension following coronary artery bypass graft (CABG).
  
  
  METHODS
  Clinical prospective, randomised study.
  
  
  METHODS
  40 patients ASA II or III, mean age 66 +/- 8 years, scheduled for elective CABG were included. If the mean arterial pressure (MAP) was > or = 100 mmHg within the first six post operative hours, the patients were included and randomly attributed to either one of the 2 groups: Gr I (n = 20) received nicardipine, Gr II (n = 20) received isradipine in bolus then in continuous perfusion. HR, MAP, MPAP, CVP, PCWP, CI, SVRI, PVRI and SVI were recorded at: T0 before administration of drugs, T1 = 2 min after the first bolus. T2 when MAP reached 85 +/- 5 mmHg. T3, T4, T5, T6, T7 and T8 at 5, 10, 30, 60, 90 and 120 min after the continuous perfusion. T9 before stopping the perfusion.
  
  
  RESULTS
  No significant changes in HR, CVP, PCWP, MPAP or PVRI at any time in both groups. Significant increase in CI at T2 in both groups. Reduction of MAP at T2 was more important (-27%) in Gr I compared to that in Gr II (-22%). This was mainly due to a significant decrease in SVRI.
  
  
  CONCLUSIONS
  Isradipine is effective in the treatment of arterial hypertension following CABG. However there is not any significant beneficial effect of isradipine over nicardipine.
authors.affiliation: Département d'anesthésie-réanimation, hôpital Hôtel-Dieu de France, Beyrouth, Liban. smj20@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Madi-Jebara
authors.forename: D
authors.initials: D
authors.lastname: Khater-Rassi
authors.forename: A
authors.initials: A
authors.lastname: Yazigi
authors.forename: F
authors.initials: F
authors.lastname: Haddad
authors.forename: G
authors.initials: G
authors.lastname: Hayek
authors.forename: R
authors.initials: R
authors.lastname: Achkouty
authors.forename: M C
authors.initials: MC
authors.lastname: Antakly
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D017275:Isradipine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D009529:Nicardipine; D017275:Isradipine